AstraZeneca Sues Barr Over Crohn's Disease Drug
AstraZeneca filed the suit on May 22 in the U.S. District Court for the District of Delaware, claiming Barr's abbreviated new drug application to sell 3-milligram budesonide enteric coated capsules infringes two patents covering Entocort.
AstraZeneca is seeking an order to prevent FDA approval of the ANDA until the patents expire, as well as costs and expenses associated with the lawsuit. The patents were issued...
To view the full article, register now.